NPPA and myeloid sarcoma: Therefore, KP profile during disease progression consists of its own activation in the active phase of MS, which leads to an increase in KYNA levels and QA production, while these KYNA levels decrease in the progressive phase of the disease, converting KP metabolites into neurotoxic molecules [63,76,78].